Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Viking Therapeutics

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.

Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027

Coinbase

General Electric

Johnson & Johnson

Microsoft

Taiwan Semiconductor Manufacturing

If you're wondering which stocks to buy in April, here's a good place to start. The stock market is off to a difficult start in the second quarter.

All-Time High Flyers: 7 Stocks to Buy as the Market Peaks

DexCom

The burgeoning interest in obesity drugs, particularly GLP-1 products such as Ozempic, Saxenda, and Mounjaro, marks a significant shift in the global approach to managing obesity. In this article, we look at three obesity drug stocks investors should consider.

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

Amgen

Ascendis Pharma

Cytokinetics

Edwards Lifesciences

Tema Obesity & Cardiometabolic ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

Medtronic

SPDR S&P 500 ETF Trust

Vertex Pharmaceuticals

Health Care Select Sector SPDR Fund

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

Veeva Systems

Novo Nordisk is a leader in fast-growing therapeutic areas. Veeva Systems' services are invaluable to its customers.

2 Healthcare Stocks to Buy Hand Over Fist in April

Health insurers are going to offer coverage for Wegovy to Medicare patients. Beyond weight loss, Wegovy has shown it can reduce the risk of heart attacks and strokes.

Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development

ASML Hld

AstraZeneca

Diageo

Hermes International

HSBC Holdings

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Nestle SA

Novartis

Prosus NV

Roche Holding AG

SAP SE

Siemens AG

Sanofi

TotalEnergies SE

Unilever

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

Catalent

The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday.

Novo Nordisk parent refiles US application on Catalent deal

Novo Nordisk and Eli Lilly make medicines that target GLP-1, which figures in a number of ailments. A new study found that a similar drug could help treat Parkinson's.

Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?

People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, according to new research.

Wegovy's heart benefits are not just linked with weight loss, new study suggests

Novo Nordisk dominates the obesity care and diabetes markets thanks to Ozempic, Rybelsus, and Wegovy. Notably, Wegovy was recently granted an expanded indication to treat patients at risk of heart disease.

After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves

A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the New England Journal of Medicine reported on Thursday.

Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial

United Therapeutics

The healthcare sector is a constant source of innovation and growth. Yet, even amidst the spotlight on industry giants, a realm of underappreciated gems still exists.

3 Underappreciated Healthcare Stocks to Buy Now: April 2024

Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.

Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion

Costco

Costco and its healthcare partner Sesame have started offering weight-loss drugs including Ozempic to Costco members. Under a $179 three-month prescription plan, members will have access to video consultations with a weight-loss doctor and an individualized, clinically-appropriate treatment program.

Costco begins offering Novo Nordisk's Ozempic to members

Star Bulk Carriers

Towards the end of the just completed first quarter, U.S.-based hedge funds began dumping American equities and shifting capital into European stocks. In an analysis, investment bank Morgan Stanley (NYSE: MS ) found that hedge funds “have bought EU equities in nearly 70% of the trading sessions” since the European stock market began to rally in January of this year.

Hedge Fund Favorites: 3 European Stocks Attracting Significant U.S. Investment

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts Think Novo Nordisk (NVO) Is a Good Investment: Is It?

Forget AI plays, meme stocks, gold, even cocoa futures — the biggest bull market right now is in equity acronyms.

The Seven Wonders of Europe adds to bull market in acronyms

Eiger BioPharmaceuticals

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Healthcare stocks fade as obesity-drug optimism fades

Novo Nordisk (NVO) closed at $127.55 in the latest trading session, marking a -0.66% move from the prior day.

Here's Why Novo Nordisk (NVO) Fell More Than Broader Market

AbbVie

HCA Healthcare

Intuitive Surgical

UnitedHealth Group

These seven healthcare companies are industry and market leaders. They generally present excellent long-term prospects, too.

Meet The "Magnificent Seven" of Healthcare Stocks

Novo Nordisk's business is not only growing at a fast rate; it also generates impressive margins. Demand for its products is strong and could increase in the years ahead.

Is Novo Nordisk the Best Healthcare Stock for You?

Novo Nordisk is buying Cardior, a clinical-stage biotech that is developing heart disease drugs. Its cardiovascular disease pipeline will get a lot stronger as a result of the acquisition.

Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock

Omega Therapeutics

Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung cancer, and obesity. Omega Therapeutics has signed a collaboration with Novo Nordisk to develop a drug for obesity management, validating the potential of its platform.

Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg. Viking Therapeutics' VK2735 has emerged as a strong contender in the GLP-1 drug market, with promising weight loss results in clinical studies.

Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data

News for Novo Nordisk Stock (NVO)